drugset / Trial / NCT02772627
Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to investigate the tolerability and safety of three multiple dose regimens of nebicapone (BIA 3-202 100 mg, 200 mg, and 300 mg 6 times daily) in healthy volunteers. To characterise the steady-state pharmacokinetic and erythrocyte COMT inhibition profiles of nebicapone in healthy volunteers.
Timeline
- Start
- 2001-09
- Primary completion
- 2001-12
- Completion
- 2001-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nebicapone | Small molecule | 100 mg | Oral |
| Subject | Nebicapone | Small molecule | 200 mg | Oral |
| Subject | Nebicapone | Small molecule | 300 mg | Oral |